Ceryvyn Therapeutics Ltd
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a OPT.AX research report →
Price Chart
About the company
Opthea Limited is an Australian clinical-stage biopharmaceutical company focused on developing and commercializing therapies primarily for eye diseases. The foundation of its development efforts lies in its intellectual property portfolio, which targets Vascular Endothelial Growth Factors (VEGF-C, VEGF-D, and VEGF Receptor-3). This technology is designed to address conditions linked to the growth of blood and lymphatic vessels, as well as vascular leakage.
- CEO
- Jeremy Max Levin Ba Zoology Dphil Mb Bchir
- IPO
- 1988
- Employees
- 33
- HQ
- South Yarra, VIC, AU
Get TickerSpark's AI analysis on OPT.AX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
Latest fiscal year · YoY change
- Revenue
- $221.83K-43.5%
- Gross Profit
- $221.83K-43.5%
- Op Income
- $-236,664,782
- Net Income
- $-247,344,645+25.1%
- EPS
- $-0.13+62.9%
- OCF Growth
- +1.5%
- FCF Growth
- +1.5%
- 52W High
- $0.60
- 52W Low
- $0.01
- 50D MA
- $0.24
- 200D MA
- $0.51
- Beta
- 1.53
- RSI (14)
- 14
- Avg Volume
- 27.82M
No earnings-call transcripts are available for OPT.AX yet.
- Free Float
- 84.1%
- Shares Outstanding
- 1.37B
- Float Shares
- 1.15B
Our OPT.AX coverage
Recent articles, reports, and earnings notes.
No research on OPT.AX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate OPT.AX report →